The Cancer Letter

Inside information on cancer research and drug development

In Brief

Amy Jo Jenkins, Matthew Kovak named to leadership positions at UAMS Winthrop P. Rockefeller Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Amy Jo Jenkins was named associate director of administration for the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences. Succeeding Jenkins, Matthew Kovak was promoted to executive director of the clinical trials office.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Researchers identify biological signature that may identify refractory ovarian cancer patients

Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Center, and University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account